In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) closed at $1.54 in the last session, up 8.45% from day before closing price of $1.42. In other words, the price has increased by $8.45 from its previous closing price. On the day, 0.99 million shares were traded. ENLV stock price reached its highest trading level at $1.6592 during the session, while it also had its lowest trading level at $1.44.
Ratios:
We take a closer look at ENLV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.20 and its Current Ratio is at 7.20. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 02, 2021, Reiterated its Buy rating but revised its target price to $33 from $22 previously.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENLV now has a Market Capitalization of 36728844 and an Enterprise Value of 16680900.
Stock Price History:
The Beta on a monthly basis for ENLV is 0.80, which has changed by 0.15789473 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, ENLV has reached a high of $1.76, while it has fallen to a 52-week low of $0.81. The 50-Day Moving Average of the stock is 39.18%, while the 200-Day Moving Average is calculated to be 36.35%.
Shares Statistics:
According to the various share statistics, ENLV traded on average about 107.34K shares per day over the past 3-months and 327890 shares per day over the past 10 days. A total of 23.85M shares are outstanding, with a floating share count of 22.66M. Insiders hold about 5.00% of the company’s shares, while institutions hold 13.85% stake in the company. Shares short for ENLV as of 1752537600 were 294417 with a Short Ratio of 2.74, compared to 1749772800 on 75282. Therefore, it implies a Short% of Shares Outstanding of 294417 and a Short% of Float of 1.2899999500000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Enlivex Therapeutics Ltd (ENLV) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.58 and -$0.58 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.59, with 1.0 analysts recommending between -$0.59 and -$0.59.
